GRI Bio GRI
NASDAQ GRI
$1.67 -0.06 (-3.47%)
At close: Aug 20, 2026 · 4:00 PM EDT

GRI Bio (GRI) Total Debt (2020)

GRI Bio (GRI) posted quarterly Total Debt of $14000.0 for Q4 2020.

GRI Bio (GRI) Total Debt (2020) Analysis & Trends

GRI Bio's Total Debt history runs 1 years deep, the most recent figure standing at $14000.0 for Q4 2020.

  • In Q4 2020, Total Debt changed N/A year-over-year to $14000.0; the TTM figure through Dec 2020 stood at $14000.0 (changed N/A YoY), while the FY2020 annual figure was $14000.0, changed N/A from the prior year.
  • Total Debt for Q4 2020 stood at $14000.0.
  • The five-year high for Total Debt was $14000.0 in Q4 2020, with the low at $14000.0 in Q4 2020.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Vertex Pharmaceuticals 137.11 Bn 129.26 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 84.98 Bn 76.99 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 64.52 Bn 59.33 Bn 1.37 Bn -
4 Moderna 53.23 Bn 48.09 Bn 52.00 Mn 591.00 Mn
5 BeOne Medicines 41.23 Bn 36.14 Bn 1.53 Bn 1.07 Bn
6 Alnylam Pharmaceuticals 30.65 Bn 27.34 Bn 992.69 Mn -
7 Insmed 27.15 Bn 25.99 Bn 358.27 Mn 546.77 Mn
8 Royalty Pharma 26.98 Bn 26.14 Bn - 9.34 Bn
9 BioNTech SE 26.78 Bn 8.39 Bn 668.28 Mn 770.36 Mn
10 GRI Bio 3.07 Mn 3.07 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2020 14,000.00